Post-GWAS Validation of Target Genes Associated with HbF and HbA₂ Levels

Area of Science:

• Genetics
• Molecular Biology
• Hematology

Background:

• Genome-Wide Association Studies (GWASs) identify numerous trait-associated variants, but in vivo validation for therapeutic development is often delayed.
• Beta-hemoglobinopathies, including sickle cell disease (SCD), face challenges with current curative therapies like bone marrow transplantation and gene therapy.
• Identifying modulators of fetal hemoglobin (HbF) and hemoglobin A2 (HbA2) is a key strategy for developing new treatments.

Purpose of the Study:

• To perform post-GWAS in vivo validation of CCND3 and NFIX, genes previously linked to HbF and HbA2 levels.
• To assess the therapeutic potential of CCND3 and NFIX in the context of beta-hemoglobinopathies.

Main Methods:

• In vivo validation studies were conducted on the CCND3 and NFIX genes.
• Gene expression levels of globin and regulatory factors were analyzed.

Main Results:

• Absence of Ccnd3 expression in vivo significantly increased gamma (HbF) and delta (HbA2) globin gene expression.
• Nfix was confirmed to be associated with gamma-globin gene expression.
• Data suggests a potential role for Nfix in regulating Klf1, a key regulator of hemoglobin switching.

Conclusions:

• CCND3 is a promising therapeutic target for sickle cell disease (SCD).
• Nfix may play a role in regulating hemoglobin switching through Klf1.
• This study bridges the gap between GWAS discovery and therapeutic target validation for beta-hemoglobinopathies.